» Articles » PMID: 21700995

Prospective Evaluation of Reader Performance on MDCT in Characterization of Cystic Pancreatic Lesions and Prediction of Cyst Biologic Aggressiveness

Overview
Specialties Oncology
Radiology
Date 2011 Jun 25
PMID 21700995
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Our objective was to evaluate the accuracy of MDCT features of pancreatic cystic lesions in cyst characterization and in predicting cyst biologic aggressiveness.

Subjects And Methods: In this prospective study, 114 patients (40 men and 74 women; age range, 23-89 years) with 130 cystic lesions (size range, 31-160 mm) in the pancreas underwent contrast-enhanced dual-phase (n = 92) and portal phase (n = 22) examinations with 16- or 64-MDCT scanners. Using defined morphologic features of cystic lesions on MDCT, two readers performed blinded evaluations for cystic characterization and predicting biologic aggressiveness (invasive lesions, carcinoma in situ, and moderate grade dysplasias) before pancreatic surgery. Receiver operating characteristic analysis was performed to assess the accuracy of MDCT using pathologic evaluation of the surgical specimen as a reference standard.

Results: On the basis of MDCT features, the radiologic accuracy (reader 1 and reader 2) for stratifying lesions into mucinous and nonmucinous subtypes was 85% and 82% and for recognizing cysts with aggressive biology was 86% and 85%, respectively. Predictive values of MDCT were superior for lesions > 30 mm and nonmucinous lesions. Features favoring aggressive biology were main pancreatic duct dilation > 10 mm (p < 0.0001), biliary obstruction (p=0.01), mural nodule (p < 0.0001), main-duct intraductal papillary mucinous neoplasm (p < 0.0001), and advanced age (p = 0.0001). Sensitivity of detecting morphologic features was higher with the dual-phase pancreatic protocol CT.

Conclusion: Morphologic features of pancreatic cystic lesions on MDCT allow reliable characterization into mucinous and nonmucinous subtypes and enable prediction of biologic aggressiveness.

Citing Articles

Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications.

Preuss K, Thach N, Liang X, Baine M, Chen J, Zhang C Cancers (Basel). 2022; 14(7).

PMID: 35406426 PMC: 8997008. DOI: 10.3390/cancers14071654.


Cystic Neoplasms of the Pancreas: Differential Diagnosis and Radiology Correlation.

Hu F, Hu Y, Wang D, Ma X, Yue Y, Tang W Front Oncol. 2022; 12:860740.

PMID: 35299739 PMC: 8921498. DOI: 10.3389/fonc.2022.860740.


Multi-Phase CT-Based Radiomics Nomogram for Discrimination Between Pancreatic Serous Cystic Neoplasm From Mucinous Cystic Neoplasm.

Gao J, Han F, Wang X, Duan S, Zhang J Front Oncol. 2021; 11:699812.

PMID: 34926238 PMC: 8672034. DOI: 10.3389/fonc.2021.699812.


Cystic pancreatic lesions: MR imaging findings and management.

Morana G, Ciet P, Venturini S Insights Imaging. 2021; 12(1):115.

PMID: 34374885 PMC: 8355307. DOI: 10.1186/s13244-021-01060-z.


Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods.

Han X, Yang J, Luo J, Chen P, Zhang Z, Alu A Front Oncol. 2021; 11:606677.

PMID: 34367940 PMC: 8339967. DOI: 10.3389/fonc.2021.606677.